Ehlers-Danlos Syndrome: Immunologic contrasts and connective tissue comparisons.
Islam, Mareesa, Chang, Christopher, Gershwin, M Eric · Journal of translational autoimmunity · 2021 · DOI
Quick Summary
This review article explains Ehlers-Danlos Syndrome (EDS), a group of inherited disorders that affect connective tissue in the body, causing symptoms like loose, stretchy skin and flexible joints. The authors describe the 13 different types of EDS, how doctors diagnose them, and how they're treated. While some forms of EDS involve inflammation, the exact mechanisms causing the disease are not fully understood.
Why It Matters
This review is relevant to ME/CFS patients because EDS—particularly hypermobile EDS—is commonly comorbid with or misdiagnosed as ME/CFS, and both conditions involve connective tissue and immune dysfunction. Understanding the distinctions between EDS and ME/CFS helps clarify differential diagnosis and may inform treatment approaches for patients with overlapping symptoms. The article's discussion of immunologic mechanisms in EDS provides context for understanding how connective tissue disorders can contribute to systemic symptoms.
Observed Findings
EDS comprises 13 recognized subtypes with varying severity from mild skin hyperextensibility to life-threatening vascular rupture
Multiple gene variants have been identified in specific EDS subtypes
Some EDS subtypes present with accompanying inflammation, though mechanisms remain unclear
Differential diagnosis requires clinical examination, family history, laboratory testing, and imaging
Surgical management carries elevated risk due to connective tissue fragility and poor wound healing
Inferred Conclusions
Accurate EDS diagnosis requires comprehensive evaluation integrating multiple diagnostic modalities and careful differentiation from overlapping conditions
Connective tissue pathology in EDS has immunologic components that warrant further investigation
Management approaches must be individualized based on EDS subtype and comorbidities to balance therapeutic benefit against surgical risk
Quality of life is significantly diminished in EDS due to both phenotypic manifestations and psychosocial impact
Remaining Questions
What are the precise immunologic mechanisms underlying inflammation in specific EDS subtypes?
What This Study Does Not Prove
This narrative review does not provide original research data, experimental results, or quantitative evidence about disease mechanisms. It does not establish causal relationships between genetic variants and clinical features, nor does it measure the prevalence of comorbidity between EDS and ME/CFS or demonstrate therapeutic efficacy of any specific treatment. The inclusion of ME/CFS in the differential diagnosis list does not imply equivalence or shared pathophysiology between the conditions.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.